"PHASE II RANDOMIZED, OBSERVER-BLIND, PLACEBO-CONTROLLED, MULTI-COUNTRY STUDY IN HEALTHY NON-PREGNANT WOMEN 18-45 YEARS OF AGE TO EVALUATE THE SAFETY, REACTOGENICITY AND IMMUNOGENICITY OF A SINGLE INTRAMUSCULAR DOSE OF GSK BIOLOGICALS¿ INVESTIGATIONAL RSV MATERNAL VACCINE (GSK388550A) WHEN GIVEN ALONE AND GIVEN IN COADMINISTRATION WITH A SINGLE INTRAMUSCULAR DOSE OF BOOSTRIX (US FORMULATION SB776423 OR EX-US FORMULATION SB263855)."
- Registry ID
- 209141 (RSV MAT-011)
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE2
- Study type
- INTERVENTIONAL
- Sponsor
- GLAXOSMITHKLINE INC
- Start date
- 2021-07-19
- Last update
- 2019-10-23
Conditions
- RESPIRATORY SYNCYTIAL VIRUS
Related clinical trials
- A PHASE 3 STUDY TO EVALUATE THE EFFICACY, IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL (RSV) PERFUSION F SUBUNIT VACCINE IN ADULTS
- A PHASE 3B, OPEN-LABEL STUDY TO
EVALUATE THE NON-INFERIORITY OF THE IMMUNE RESPONSE AND TO EVALUATE THE SAFETY OF THE RSVPREF3 OA
INVESTIGATIONAL VACCINE IN ADULTS 18-49 YEARS OF AGE AT INCREASED RISK FOR RESPIRATORY SYNCYTIAL VIRUS
DISEASE, COMPARED TO OLDER ADULTS ¿60 YEARS OF AGE
- AN INTERVENTIONAL PHASE 2/3, ADAPTIVE, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND STUDY TO INVESTIGATE EFFICACY AND SAFETY OF ORAL SISUNATOVIR COMPARED WITH PLACEBO IN NON-HOSPITALIZED SYMPTOMATIC ADULTS WITH RESPIRATORY SYNCYTIAL VIRUS INFECTION WHO ARE AT RISK OF PROGRESSION TO SEVERE ILLNESS
- A PHASE 3 STUDY TO EVALUATE THE IMMUNOGENICITY AND SAFETY OF MRNA-1345, AN
MRNA VACCINE TARGETING RESPIRATORY SYNCYTIAL VIRUS, IN HIGH-RISK ADULTS
- A PHASE III, OPEN-LABEL, RANDOMIZED, CONTROLLED, MULTI-COUNTRY STUDY TO EVALUATE
THE IMMUNE RESPONSE, SAFETY AND REACTOGENICITY OF RSVPREF3 OA INVESTIGATIONAL
VACCINE WHEN CO-ADMINISTERED WITH HERPES ZOSTER RECOMBINANT SUBUNIT (HZ/SU)
VACCINE IN ADULTS AGED 50 YEARS AND OLDER
- A PHASE 3, OBSERVER-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE NONINFERIORITY OF THE IMMUNE RESPONSE AND SAFETY OF THE RSVPREF3 OA INVESTIGATIONAL VACCINE IN ADULTS 50-59 YEARS OF AGE, INCLUDING ADULTS AT INCREASED RISK OF RESPIRATORY SYNCYTIAL VIRUS LOWER RESPIRATORY TRACT DISEASE, COMPARED TO OLDER ADULTS ¿60 YEARS OF AGE
View on source registry